TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8435812

Group type: COMPARATOR
Intervention: Accelerated hyperfractionated radiation therapy at 48 Gy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy at 54.4 Gy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy at 64 Gy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy at 70.4 Gy
Number of subjects: 153
Study: 3599794

Group type: EXPERIMENTAL
Intervention: Coarse‐grained breads
Number of subjects: 103

Group type: COMPARATOR
Intervention: Finer grained breads or breads produced from flour
Number of subjects: 103
Study: 28107027

Group type: EXPERIMENTAL
Intervention: Play-based intervention targeting executive functions and parent-child relationships
Number of subjects: 68
Study: 29056608

Group type: EXPERIMENTAL
Intervention: Fitbit One device
Number of subjects: 36
Study: 26553413

Group type: EXPERIMENTAL
Intervention: Endourethral collagen type 2 injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Endourethral saline water injection
Number of subjects: 24
Study: 23992605

Group type: EXPERIMENTAL
Intervention: 30-40 mm Hg graduated compressive stockings (GCS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No stockings
Number of subjects: 69
Study: 22648218

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin 1% gel (BPO/C)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Adapalene 0.1% gel (AP)
Number of subjects: 168
Study: 19601709

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 300 microg subcutaneously Q3W
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 17525166

Group type: EXPERIMENTAL
Intervention: valdecoxib 20 mg bid
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: valdecoxib 40 mg qd
Number of subjects: 197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study: 15302981

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: eprosartan 600 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 119
Study: 12049152

Group type: EXPERIMENTAL
Intervention: Tofu (6 oz/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tofu + Orange Juice (6 oz tofu + 303 mg vitamin C/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (T group)
Number of subjects: 14
Study: 9834279

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg twice daily for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Imipenem 500 mg three times daily for 2 weeks
Number of subjects: 60
Study: 8115618

Group type: EXPERIMENTAL
Intervention: Ionic contrast agent
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nonionic contrast agent
Number of subjects: 46
Study: 2552740

Group type: EXPERIMENTAL
Intervention: 300 micrograms immune globulin anti-D administered prenatally
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control group (354 women who did not receive prenatal immune globulin)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Prenatal prophylaxis group
Number of subjects: 609
Study: 1255329

Group type: EXPERIMENTAL
Intervention: Experimental group (124 children)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (122 children)
Number of subjects: 246
Study: 31254681

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at TE3 and TE5 for 30 minutes
Number of subjects: 54
Study: 27931887

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 25263212

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731
Study: 23182627

Group type: EXPERIMENTAL
Intervention: Tivantinib (360 mg twice‐daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tivantinib (240 mg twice‐daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tivantinib (for MET-high tumours)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (for MET-high tumours)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tivantinib 360 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Tivantinib 240 mg
Number of subjects: 107
Study: 21817157

Group type: EXPERIMENTAL
Intervention: Simultaneous intratympanic dexamethasone with systemic steroids
Number of subjects: 88

Group type: COMPARATOR
Intervention: Subsequent intratympanic dexamethasone given 7 days after systemic treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Subsequent intratympanic dexamethasone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone treatment
Number of subjects: 88
Study: 19118304

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg per day for 3 years
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Alendronate (various doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Alendronate treatment discontinued for 1 year
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16836917

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 41
Study: 15522047

Group type: EXPERIMENTAL
Intervention: CEqual program for quantifying size of perfusion defects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cedars‐Sinai quantitative gated single‐photon emission tomography program for quantifying left ventricular function
Number of subjects: 13
Study: 11195997

Group type: EXPERIMENTAL
Intervention: PerMag participants
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: SocAnh participants
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 159
Study: 9030681

Group type: EXPERIMENTAL
Intervention: 16 oz of yogurt containing live, active Lactobacillus bulgaricus and Streptococcus thermophilus
Number of subjects: 20

Group type: COMPARATOR
Intervention: 16 oz of milk (2% milk)
Number of subjects: 20
Study: 8301102

Group type: EXPERIMENTAL
Intervention: Cyclosporin (12 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cyclosporin (30 mg/kg)
Number of subjects: 10
Study: 4029186

Group type: EXPERIMENTAL
Intervention: Predictive index based on clinical variables available at discharge (history of hypertension, angina pectoris, diabetes, maximal serum ASAT during MI)
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: New predictive index including cessation of smoking after MI
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: Reinfarctions occurring before the median follow‐up time of 21 months
Number of subjects: 1306
Study: 31840832

Group type: EXPERIMENTAL
Intervention: Revision ACL reconstruction
Number of subjects: 0
Study: 29523409

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control
Number of subjects: 522
Study: 26782346

Group type: EXPERIMENTAL
Intervention: PPV plus dexamethasone (1mg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dexamethasone (1mg/d) alone
Number of subjects: 72
Study: 24831979

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, orally)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2, intravenously, every 21 days, or docetaxel 75 mg/m2, intravenously, every 21 days)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 285
Study: 21422847

Group type: EXPERIMENTAL
Intervention: E2 valerate and dienogest
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 16444091

Group type: EXPERIMENTAL
Intervention: Indoor exercise (30 min treadmill walk, 5 days/week at 60% of maximal heart rate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Outdoor exercise (30 min track walking, 5 days/week at 60% of maximal heart rate)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 90
Study: 12472488

Group type: EXPERIMENTAL
Intervention: Human Skin Substitute (HSS) applied to 6 patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Secondary intention healing applied to 6 patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Human Skin Substitute (HSS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Secondary intention healing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Human Skin Substitute (HSS) and Secondary intention healing
Number of subjects: 12
Study: 10682566

Group type: EXPERIMENTAL
Intervention: 1,6‐diphosphate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 8746044

Group type: EXPERIMENTAL
Intervention: Short chain fatty acids enema (acetate: 60 mmol/L; propionate: 30 mmol/L; n-butyrate: 40 mmol/L) administered twice a day for 14 days (group 1; n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Isotonic NaCl enema (group 2; n = 6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (16 volunteers, mean age: 27 years)
Number of subjects: 13
Study: 2796619

Group type: EXPERIMENTAL
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL + 15 microgram clonidine (Gr.2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL + 30 microgram clonidine (Gr.3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL + 45 microgram clonidine (Gr.4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tetracaine 10 mg in 10% glucose solution 2 mL (Control Group)
Number of subjects: 60
Study: 101313

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 0
Study: 31761541

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a dose prescription of 40 Gy in 5 fractions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized dose constraints and clinical target volume delineation for SBRT.
Number of subjects: 0
Study: 29753118

Group type: EXPERIMENTAL
Intervention: Intraarticular onabotulinumtoxinA 400 U
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Intraarticular onabotulinumtoxinA 200 U
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 176
Study: 26954978

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 26564673

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation and Confinement (SDC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Manual operation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixed operation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High complexity operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 23349295

Group type: EXPERIMENTAL
Intervention: Treatment in a specialised out‐patient mood disorder clinic
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard out-patient treatment
Number of subjects: 158
Study: 19487105

Group type: EXPERIMENTAL
Intervention: Salmon (150g three times per week, resulting in a daily consumption of 2.1g of omega-3 long-chain polyunsaturated fatty acids)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (1.3g of omega-3 long-chain polyunsaturated fatty acids per day)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Cod (150g three times per week, resulting in a daily consumption of 0.3g of omega-3 long-chain polyunsaturated fatty acids)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study: 18091010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 microg SAL (D2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 microg SAL (D4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 800 microg SAL (D8)
Number of subjects: 30
Study: 16541302

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 5187
Study: 14700263

Group type: EXPERIMENTAL
Intervention: Open-eruption surgical-orthodontic technique
Number of subjects: 12
Study: 11195717

Group type: EXPERIMENTAL
Intervention: Continuous visuomotor compensatory tracking task during sleep deprivation
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: EEG power changes during drowsiness
Number of subjects: 4
Study: 8698447

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10 to 40 mg/d), with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 1470824

Group type: EXPERIMENTAL
Intervention: Micronized progesterone administered intra‐vaginally (600 mg/d)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Progesterone in solution in oil (50 mg/day) administered by intramuscular injection
Number of subjects: 272
Study: 6362694

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine with adrenaline 5 micrograms ml‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine with adrenaline 5 micrograms ml‐1
Number of subjects: 40
Study: 31083368

Group type: EXPERIMENTAL
Intervention: Meeting both physical activity and screen time recommendations
Number of subjects: 2321

Group type: COMPARATOR
Intervention: Not meeting both physical activity and screen time recommendations
Number of subjects: 2321
Study: 30528686

Group type: EXPERIMENTAL
Intervention: DDDRP + MVP (Atrial preventive pacing and atrial antitachycardia pacing)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard dual-chamber pacing (DDDR)
Number of subjects: 100
Study: 26657213

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation sessions focusing on memory strategy (10 sessions)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Active therapy sessions (placebo control)
Number of subjects: 65
Study: 24674576

Group type: EXPERIMENTAL
Intervention: Bifocal treatment (+1.75 add) during the 3-year period in childhood
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Short reading distance in childhood
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Time spent on sports and outdoor activities in childhood
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Time spent on reading and close work in childhood
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Watching television <3 hours daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mean myopic progression 8 years after age 20-24
Number of subjects: 240
Study: 22527106

Group type: EXPERIMENTAL
Intervention: Standard treatment plus patient support program
Number of subjects: 503

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Patient centered care questionnaire
Number of subjects: 503
Study: 20357369

Group type: EXPERIMENTAL
Intervention: 0.25 microg 1,25(OH)(2)D(3) daily for 9 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 18556967

Group type: EXPERIMENTAL
Intervention: Compensated Insulin Resistance (CIR)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Decompensated Insulin Resistance (DIR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal Insulin Sensitivity (NIS)
Number of subjects: 73
Study: 15883215

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Glimepiride (2.7 mg/d)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 173
Study: 11817924

Group type: EXPERIMENTAL
Intervention: Demographic and psychosocial factors (e.g., race, academic rank, depressive symptomatology, self-reported value of health, appearance, and achievement, parenting style)
Number of subjects: 3798
Study: 10365063

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 50
Study: 8963917

Group type: EXPERIMENTAL
Intervention: Daily ingestion of 30 mg of beta-carotene supplements
Number of subjects: 0
Study: 1704989

Group type: EXPERIMENTAL
Intervention: Metoprolol (M) 100 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cilazapril (C) 2.5 mg daily
Number of subjects: 12
Study: 7372828

Group type: EXPERIMENTAL
Intervention: Assertion training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delay-control
Number of subjects: 26
Study: 31756304

Group type: EXPERIMENTAL
Intervention: Genomic findings (secondary/incidental)
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Positive attitudes towards genetic testing
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Higher subjective numeracy
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Higher absolute risk, preventability, reproductive risk, positive attitudes towards genetic testing
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Positive attitudes towards genetic testing, younger age
Number of subjects: 2075
Study: 28455996

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 16
Study: 25826479

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 23420622

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for personality disorders (CBTpd) plus Treatment as Usual
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 106
Study: 21848799

Group type: EXPERIMENTAL
Intervention: Esomeprazole (7 weeks treatment)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo (7 weeks treatment)
Number of subjects: 1250
Study: 20008236

Group type: EXPERIMENTAL
Intervention: Emerging new treatment modalities under investigation for relapsed classical Hodgkin lymphoma
Number of subjects: 0
Study: 16973256

Group type: EXPERIMENTAL
Intervention: Gosereline (3.6 mg subcutaneous injection monthly)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily per os)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gosereline
Number of subjects: 32

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 32
Study: 15029004

Group type: EXPERIMENTAL
Intervention: Two days' training on diabetic foot management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11440901

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comparison of id and iv glucose infusion
Number of subjects: 14
Study: 10052045

Group type: EXPERIMENTAL
Intervention: PVP tube
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silicone tube
Number of subjects: 50
Study: 8000630

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium (Voltarol; Ciba‐Geigy)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2969320

Group type: EXPERIMENTAL
Intervention: Monophasic ethinylestradiol (EE) + desogestrel (DG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Triphasic ethinylestradiol (EE) + levonorgestrel (LNG)
Number of subjects: 36
Study: 30663184

Group type: COMPARATOR
Intervention: Clotrimazole (100 mg vaginal tablet, once daily for 7 days)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Salvia officinalis (400 mg vaginal tablet, once daily for 7 days)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Combination of Salvia officinalis and Clotrimazole (once daily for 7 days)
Number of subjects: 111
Study: 29399825

Group type: EXPERIMENTAL
Intervention: Tele-Savvy (active condition)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study: 27016296

Group type: EXPERIMENTAL
Intervention: Intraoperative cytological assessment of bone margins (ICAB)
Number of subjects: 102
Study: 24148807

Group type: EXPERIMENTAL
Intervention: Active conservative treatment (pelvic floor muscle training and bladder training)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 747
Study: 22968556

Group type: EXPERIMENTAL
Intervention: Octreotide-depo
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 594

Group type: COMPARATOR
Intervention: 5-fluorouracil and dalargin
Number of subjects: 594
Study: 20437326

Group type: EXPERIMENTAL
Intervention: Group-based Cognitive Strategy Training (CST)
Number of subjects: 21
Study: 17907482

Group type: EXPERIMENTAL
Intervention: Quell Desensitizer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium fluoride solution (Nupro Neutral)
Number of subjects: 30
Study: 16037105

Group type: EXPERIMENTAL
Intervention: Preterm birth (before 37 completed weeks)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Babies born before 37 completed weeks but after 32 weeks
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Babies born between 24 and 33 weeks gestation
Number of subjects: 512
Study: 10943871

Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate, cyclosporin A, and corticosteroids)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 82
Study: 9116921

Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study: 8330601

Group type: EXPERIMENTAL
Intervention: Posterior approach to interscalene block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral approach to interscalene block
Number of subjects: 0
Study: 3570867

Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Banked drip breast milk (BBM)
Number of subjects: 0